✦ LIBER ✦

Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia

✍ Scribed by Boccia, Ralph ;Zighelboim, Jacob ;Champlin, Richard E. ;Kim, Chun Choo ;Gale, Robert Peter

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 186 KB
Volume: 12
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950120307

No coin nor oath required. For personal study only.

✦ Synopsis

27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders

📜 SIMILAR VOLUMES

Phase II trial of plicamycin and hydroxy

Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia

✍ Eric Archimbaud; Jacques Troncy; Catherine Sebban; Denis Guyotat; Yves Devaux; M 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 229 KB

A phase II trial of m-AMSA in head and n

A phase II trial of m-AMSA in head and neck cancer

✍ Arlene A. Forastiere; Charles W. Young; Robert E. Wittes 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 160 KB

A phase I and II study of m-AMSA in acut

A phase I and II study of m-AMSA in acute leukaemia

✍ M. L. Slevin; M. S. Shannon; H. G. Prentice; A. J. Goldman; T. A. Lister 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 279 KB

Phase II study of low-dose continuous in

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

✍ Hagop M. Kantarjian; Michael J. Keating; Ronald S. Walters; Charles A. Koller; K 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB 👁 2 views

Phase I–II trial of mitoxantrone in acut

Phase I–II trial of mitoxantrone in acute leukemia: an interim report

✍ Zalmen A. Arlin; Gary Dukart; Ingrid Schoch; Arnold Reisman; Joseph Moore; Richa 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 302 KB

Phase II trial of ICRF-187 in children w

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

✍ Tribhawan Vats; Barton Kamen; Jeffrey P. Krischer 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

ICRF-187 is the ( + ) enantiomer of the racemic mixture razoxane . This compound is much more water soluble and thus could be formulated for parental use. The maximum tolerated dose in children after phase I trials was determined to be 3500 mg/MVday x 3 days. A phase II trial of ICRF-187 was done in